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ABSTRACT
Probiotics offer various health benefits. Lactobacillus plantarum has been used for decades to 
enhance human intestinal mucosal immunity and improve skin barrier integrity. Extracellular 
vesicles (EVs) derived from eukaryotic or prokaryotic cells have been recognized as efficient 
carriers for delivery of biomolecules to recipient cells, and to efficiently regulate human patho-
physiology. However, the mechanism underlying the beneficial effects of probiotic bacteria- 
derived EVs on human skin is unclear. Herein, we investigated how L. plantarum-derived EVs 
(LEVs) exert beneficial effects on human skin by examining the effect of LEVs on cutaneous 
immunity, particularly on macrophage polarization. LEVs promoted differentiation of human 
monocytic THP1 cells towards an anti-inflammatory M2 phenotype, especially M2b, by inducing 
biased expression of cell-surface markers and cytokines associated with M2 macrophages. Pre- or 
post-treatment with LEVs under inflammatory M1 macrophage-favouring conditions, induced by 
LPS and interferon-γ, inhibited M1-associated surface marker, HLA-DRα expression. Moreover, LEV 
treatment significantly induced expression of macrophage-characteristic cytokines, IL-1β, GM- 
CSF and the representative anti-inflammatory cytokine, IL-10, in human skin organ cultures. 
Hence, LEVs can trigger M2 macrophage polarization in vitro, and induce an anti-inflammatory 
phenomenon in the human skin, and may be a potent anti-inflammatory strategy to alleviate 
hyperinflammatory skin conditions.
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Like mammalian cells, most bacteria constitutively 
release lipid bilayer-enclosed, nanosized extracellular 
vesicles (EVs) termed outer membrane vesicles in 
gram-negative bacteria, or membrane vesicles in gram- 
positive bacteria [1–3]. These EVs contain bioactive 
molecules, including nucleic acids, proteins, lipids, tox-
ins and various virulence factors, and have diverse 
functions in cell-to-cell communication between bac-
teria and in inter-kingdom signalling. Bacterial EVs are 
more effective than bacterial extracts or purified toxins 
in evoking cellular responses in the recipient cells 
[1,4,5]. Moreover, pathogenic bacterial EVs can 
directly and potently affect the human immune system 
and cause disease even in the absence of live cells, as 
exemplified in sepsis [6–9]. Recently, gram-positive 
bacteria-derived EVs have been drawing increasing 
attention due to their effects on human health [10]. 
In particular, EVs derived from Staphylococcus aureus 
and Propionibacterium acnes, representative gram- 
positive bacteria on the human skin, are strongly asso-
ciated with the pathogenesis of atopic dermatitis and 
acne vulgaris, respectively [4,11].
In contrast to pathogen-derived EVs, probiotic bac-
teria-derived EVs have been suggested to exert bene-
ficial immunomodulatory properties, as indicated by 
findings in disease models of inflammatory colitis and 
in intestinal immune cells [12]. Probiotics were origin-
ally defined as live microorganisms that exhibit bene-
ficial effects on gut function upon administration; 
therefore, studies of probiotic bacteria, represented 
primarily by Lactobacillus and Bifidobacterium, and 
their EVs have mostly focused on their effects on the 
intestinal immune system or intestinal epithelial barrier 
function [10,13–16]. Given that the skin is another 
major habitat for microorganisms and is exposed 
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daily to various environmental cues affecting the com-
position of commensal and pathogenic bacteria, it is 
important to investigate the effects of probiotics and 
their EVs on the skin to provide a means to beneficially 
regulate the skin microflora. A recent report suggested 
that Lactobacillus plantarum-derived EVs (LEVs) can 
prevent skin inflammation in atopic dermatitis [17]; 
however, the underlying mechanism was not 
elucidated.
Macrophages, a component of the mononuclear 
phagocyte system, are part of the innate immune sys-
tem and play major roles not only in inflammation and 
host defence, but also in protective functions, including 
anti-inflammation, wound healing and tissue remodel-
ling [18,19]. Owing to their diversity and plasticity, 
mature but inactive macrophages (often referred to as 
naïve M0), which are directly differentiated from 
monocytes that have migrated into tissues, can be sub-
sequently polarized towards two distinct active states 
depending on microenvironmental signals. Classically 
activated (M1) macrophages are induced by toll-like 
receptor (TLR) and interferon (IFN) signals (lipopoly-
saccharides [LPS], IFN-γ), while alternatively activated 
(M2) macrophages are further divided into four sub-
types in response to various activating factors: M2a, 
which are induced by IL-4 and IL-13, M2b induced by 
immune complexes (antigen–antibody) in combination 
with IL-1β or LPS, M2 c induced by IL-10, transform-
ing growth factor (TGF)-β or glucocorticoids, and 
M2d/TAM induced by costimulation with TLR ligands 
and A2 adenosine receptor agonists, or by IL-6 [19– 
24]. While M1 macrophages predominate during the 
early stage of inflammation and mediate pathogenic 
clearance and the recruitment of other effector cells, 
M2 macrophages are involved in anti-inflammation, 
wound healing, tissue remodelling and vasculogenesis 
at the end of inflammation. Failure to switch from M1 
to M2 predominance, or an imbalance in their ratio, 
causes chronic inflammation and tissue damage and is 
associated with various human diseases, including 
allergic asthma, atherosclerosis, obesity, type 2 diabetes, 
autoimmune diseases and chronic skin diseases 
[21,25,26], implying that a balanced M1/M2 ratio is 
important for tissue homoeostasis. Among the various 
factors regulating M1 or M2 polarization, such as cyto-
kines, growth factors, drugs and natural products, 
(mesenchymal) stem cell- or pathogen-derived EVs 
preferentially induce polarization towards M2 or M1, 
respectively [27,28], suggesting that EVs play a role in 
macrophage polarization.
In this study, therefore, we investigated the role of 
LEVs from the probiotic strain L. plantarum APsulloc 
331261 in regulating cutaneous immunity, especially 
macrophage polarization. To this end, human mono-
cytic THP1 cells and human skin organ cultures were 
treated with LEVs, after which the expressions of var-
ious cellular markers and cytokines associated with 
macrophage states were analysed and the released cyto-
kines were determined. We further validated the effect 
of LEV treatment before or after M1 macrophage 
induction on the expression of M1-specific polarization 
markers.
Materials and methods
Purification of bacterial EVs
For separation/isolation, characterization and func-
tional studies of bacterial EVs, we followed the guide-
lines of minimal information for studies of EVs 2018 
(MISEV2018) [29]. L. plantarum APsulloc 331261 
(deposit number: KCCM11179P) was isolated from 
green tea leaves collected in the Dosun Green Tea 
Garden in Jeju, South Korea by Amorepacific R&D 
Center (Yongin, South Korea). L. plantarum APsulloc 
was grown in MRS broth at 37°C in an anaerobic 
chamber (Bactron; Sheldon Manufacturing, Cornelius, 
OR) connected to a gas cylinder containing 5% H2, 5% 
CO2 and 90% N2 for 24 h, and was then subcultured in 
the same condition following 1 to 100 dilution. 
S. aureus (ATCC 6538) was grown in BDTM Tryptic 
Soy Broth medium (Franklin Lakes, NJ) for 18–24 h at 
32°C and then subcultured in the same condition after 
1 to 100 dilution. When the culture reached an optical 
density of 1.0–1.5 at 600 nm, or reached stationary 
phase, the cells (≥ 2.7 × 109 colony-forming units 
(cfu)/mL of L. plantarum APsulloc; ≥ 8.6 × 108 cfu/ 
mL of S. aureus) were pelleted by sequential centrifu-
gation at 1800× g at 4°C for 20 min and 10,000× g at 4° 
C for 20 min. The culture supernatants (≤10 L) of 
L. plantarum APsulloc were filtered through a 0.45- 
μm membrane (Merck Millipore, Burlington, MA) and 
concentrated 10-fold using a tangential flow filtration 
(TFF) system with Pellicon 2 mini filters (Merck 
Millipore). LEVs or S. aureus-derived extracellular 
vesicles (SEVs) were purified from 10-fold culture con-
centrates or approximately 1 L-culture supernatants, 
respectively, according to a previously reported purifi-
cation method for gram-positive bacterial EVs [30]. In 
brief, the supernatants were filtered through a 0.45-μm 
filter membrane and subjected to ultracentrifugation 
(UC) at 150,000× g at 4°C for 3 h (Type 45 Ti rotor, 
Beckman Coulter, Brea, CA). The pellet was diluted in 
HEPES-buffered saline (HBS) and the total protein 
concentration was determined using a Bradford assay 
(Bio-Rad Laboratories, Hercules, CA). The 
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distribution, average diameter and particle numbers of 
EVs were measured using qNano Gold equipped NP80, 
NP150 or NP200 nanopores based on the principle of 
tunable resistive pulse sensing (TRPS) (Izon Science, 
Christchurch, New Zealand), or using Zetasizer Nano 
ZS based on dynamic light scattering (DLS) (Malvern 
Instruments, Worcestershire, UK). LEVs or SEVs pur-
ified by an UC method were investigated for their 
biological effects on human THP1 cells (10 μg/mL 
protein concentration) and skin organ cultures 
(50 μg/mL protein concentration). Medium concen-
trates from complete MRS medium that had not been 
conditioned by bacteria, yet was processed in the same 
way as conditioned medium, were prepared using the 
same procedure for LEV purification by UC and used 
as negative control for the LEV effect. To prepare 
L. plantarum ferment lysates (LFLs), cells and culture 
supernatants were ruptured under high pressure 
(>1000 bars). The fractions containing nanosized par-
ticles were then enriched by a continuous process of 
filtration through a 0.22 μm membrane (Merck 
Millipore) and ultrafiltration using a membrane mod-
ule rated at a 10 kDa-nominal molecular weight limit 
(Merck Millipore).
OptiPrep density gradient UC
Density gradient UC using OptiPrepTM [60% (w/v) 
solution of iodixanol in water; Axis-Shield PoC AS, 
Oslo, Norway] was performed according to the manu-
facturer’s protocol with specific modifications. 
A discontinuous gradient of 50%, 35% and 20% (w/v) 
iodixanol was made by mixing 50% (w/v) iodixanol 
working solution with appropriate amounts of a homo-
genization medium (HM; 0.25 M sucrose, 150 mM 
NaCl, 20 mM HEPES pH 7.4). Iodixanol working solu-
tion was prepared by mixing 5 volumes of OptiPrep 
with 1 volume of dilution medium (DM; 0.25 M 
Sucrose, 0.9 M NaCl, 120 mM HEPES pH 7.4). The 
LEV pellets after UC were dissolved in 0.417 mL of 
DM and mixed with 5 volumes (2.085 mL) of OptiPrep 
solution. Next, 2.5 mL of control (50% iodixanol 
alone), or sample in 50% iodixanol was overlaid with 
2.5 mL each of 35%, 20% and 0% solutions and cen-
trifuged at 200,000× g at 4°C for 2 h (SW 41 Ti rotor, 
Beckman Coulter). The 1 mL fractions were then col-
lected from the top of the gradient in the control tube, 
and the density of each fraction was determined via 
a standard curve created with absorbance values at 
340 nm. The EV fractions at densities between 
1.17~1.24 (between fractions 5 and 6; F5-6) were col-
lected using a 1 mL-syringe from the sample tube. To 
remove iodixanol, the fraction was diluted in 60 mL of 
HBS, ultracentrifuged at 150,000× g at 4°C for 3 h, and 
resuspended with 200 μL of HBS. LEVs purified by 
OptiPrep density gradient UC (density-purified LEVs) 
were analysed for total protein concentration using 
a Bradford assay, and their distribution, average dia-
meter and particle numbers were measured using DLS 
with Zetasizer Nano ZS or TRPS with qNano Gold. 
Density-purified LEVs were then used for validating 
the biological effects of UC-purified LEVs and for high 
resolution image analysis using bio-transmission elec-
tron microscopy (TEM) and cryo-electron micro-
scopy (EM).
Bio-TEM and cryo-EM analyses
Bio-TEM images were obtained as previously described 
[4]. In brief, density-purified LEVs were applied to 
400-mesh copper grids and negatively stained with 
2% uranyl acetate. Electron micrographs were recorded 
with a Tecnai G2 20 microscope (FEI, Hillsboro, OR) 
at an acceleration voltage of 200 kV. For cryo-EM 
analysis, 3 µL of LEVs was added to both sides of a 
Quantifoil TEM grid with a hole diameter of 1.2 μm 
and an inter-hole distance of 1.3 μm. The TEM grid 
was blotted for 1.5 s and plunged into liquid ethane 
using a Cryoplunge 2 system (Gatan, Pleasanton, CA). 
The cryo-TEM samples were stored in liquid nitrogen 
before TEM observation. The samples were examined 
under a Tecnai F20 electron microscope (FEI) operated 
at 120 kV.
Human skin organ culture
Written informed consent was obtained, and the study 
protocol was approved by the Institutional Review 
Board of the Severance Hospital at Yonsei University 
College of Medicine in Seoul, Republic of Korea (IRB 
no. 7-2017-1041). Postsurgical remnants of human 
abdominal skin from two different donors were 
obtained and prepared as previously described [31]. 
In each experiment, the tissue sample was divided 
into 1 cm × 1 cm pieces as needed for material treat-
ments including a vehicle for a negative control, and 
cultured in Dulbecco’s modified Eagle’s medium sup-
plemented with 2% foetal bovine serum and 1% peni-
cillin/streptomycin at 37°C in the presence of 5% CO2 
for six days. On days 2 and 4, vehicle or bacterial EVs 
were added in 2-mL culture medium of the tissue 
samples to a final protein concentration of 50 μg/mL. 
For cytokine array analysis, culture supernatants were 
harvested at day 6 and centrifuged at 13,000 rpm at 4°C 
for 10 min. The supernatants were then applied to the 
membranes of human cytokine antibody array C3 
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(RayBiotech, Peachtree Corners, GA) and immune 
blotting was performed following the manufacture’s 
protocol. Dot intensity for each cytokine on the mem-
brane was determined by densitometry using ImageJ 
(https://imagej.nih.gov/ij/). The tissues at day 6 were 
embedded in Tissue-Tek® O.C.T. compound (Sakura 
Finetek USA, Torrance, CA) and frozen on dryice. 
Frozen tissue sections were stained with haematoxylin 
and eosin (Abcam, Cambridge, UK).
Cell culture
Human THP1 cells were maintained in RPMI-1640 
medium supplemented with 10% FBS, 1 unit of peni-
cillin and 50 μg/mL of streptomycin (Thermo Fisher 
Scientific, Waltham, MA, USA) at 37°C in the presence 
of 5% CO2. To induce differentiation of monocytes to 
macrophages, THP1 cells were treated with 10 nM 
phorbol-12-myristate-13-acetate (PMA; Sigma- 
Aldrich) or 10 μg/mL LEVs for 48 h. To induce M1 
macrophages, THP1 cells were treated with 20 ng/mL 
of IFN-γ and 10 pg/mL of LPS (R&D Systems, 
Minneapolis, MN, USA). Cytotoxicity was measured 
using the Pierce™ LDH Cytotoxicity Assay Kit accord-
ing to the manufacturer’s instruction (Thermo Fisher 
Scientific).
Quantitative reverse transcription (RT-q)PCR
Total RNA was extracted from cells using TRIzol® 
reagent (Thermo Fisher Scientific), following the man-
ufacturer’s instructions, and was quantified using 
a NanoDrop One spectrophotometer (Thermo Fisher 
Scientific). RNA (100 ng) was reverse-transcribed using 
the iScript™ cDNA synthesis kit (Bio-Rad, Hercules, 
CA, USA), following the manufacturer’s instructions. 
qPCR was performed using a QuantStudio 3 real-time 
PCR system (Thermo Fisher Scientific) using TaqMan™ 
Gene Expression Master Mix (Thermo Fisher 
Scientific) per the manufacturer’s instructions. 
Thermal cycles were as follows: 5 min at 95°C; followed 
by 40 cycles of 15 s at 95°C and 60 s at 60°C. Primers 
and hydrolysis probe sets (TaqMan Gene Expression 
Assay) for CD14, CCR2, ICAM-1 and all TLRs 1–9 were 
purchased from Thermo Fisher Scientific. For other 
genes, gene-specific primers were designed using 
ProbeFinder software, and a matching probe was 
obtained from Universal ProbeLibrary (Roche, Basel, 
Switzerland; Supplementary Table S1). Gene expression 
was determined using the 2–ΔΔCq method, and all data 
were normalized to glucose-6-phosphate dehydrogen-
ase (G6PD) as a reference gene. Along with G6PD, 
additional reference genes, including β-actin (ACTB), 
TATA-box binding protein (TBP), ribosomal protein 
L32 (RPL32) and glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) were used to validate their consistent 
expression during culture under different cellular con-
ditions and to verify the qPCR data normalized by 
G6PD following MIQE guidelines [32].
Droplet digital (dd)PCR
Total RNA (100 ng) was reverse-transcribed using the 
iScript™ cDNA synthesis kit with MS2 RNA spike-in 
(Roche, Indianapolis, IN). The cDNA (diluted 1:10) 
was subjected to ddPCR on a QX200 Droplet Digital 
PCR System (Bio-Rad) using ddPCR Supermix for 
Probes (Bio-Rad), following the manufacturer’s 
instructions. Data acquisition and analysis were per-
formed using the in-built software (Bio-Rad) [4]. 
Primers and probes for TLRs were purchased from 
Thermo Fisher Scientific.
Statistical analysis
The preparation of LEVs using UC or density gradient UC 
methods were performed a minimum of three times. The 
aliquots of LEVs at high protein concentration purified 
from 10 L-culture by UC method were used to investigate 
biological effects. All experiments for RT-qPCR analyses in 
THP-1 cells were conducted a minimum of three times 
(three independent treatments). The experiments invol-
ving human skin cultures were performed twice using 
two independent tissue samples. Data are expressed as 
the mean ± standard error of the mean (SEM). Statistical 
significance was determined by one-way ANOVA for 
three or more groups or Student’s t-test for two groups. 
p < 0.05 was considered significant.
Results
L. plantarum APsulloc spontaneously releases EVs
We previously identified L. plantarum APsulloc 331261 
(Accession No. given by the international depositary 
authority: KCCM11179P; hereafter, referred to as 
L. plantarum) from fermented green tea leaves. LEVs 
were isolated from culture supernatants using conven-
tional UC, or density UC methods according to the 
purpose (biological effect versus high resolution image, 
respectively) (Supplementary Figure S1a). The size and 
distribution of LEVs purified by both methods was simi-
lar based on DLS analysis (Supplementary Figure S1b). 
TRPS analysis revealed that UC- and density-purified 
LEVs had a diameter of approximately 100 nm, with an 
average value of 104 ± 42.4 nm (mode diameter, 77 nm) 
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and 83 ± 20.3 nm (mode diameter, 73 nm), respectively, 
implying a wide size distribution in both purification 
methods (Figure 1(a)). The mean number of particles 
per milligram of protein was 2.13 × 109 for UC-purified 
LEVs, and 3.83 × 1010 for density-purified LEVs (Figure 
1(b)), suggesting that EVs purified by a density gradient 
UC show higher purity than those purified via conven-
tional UC methods. Given the total culture volume and 
number of cells, the yield of UC-purified LEVs was 
approximately 2.45 × 1010 per 1 L or 2.7 × 1012 cfu/L. 
According to bio-TEM and cryo-EM analyses for den-
sity-purified LEVs, LEVs had a closed spherical mem-
brane structure (Figure 1(c)), similar to previously 
described gram-positive bacteria-derived EVs [4,30]. 
Meanwhile, UC-purified LEVs (hereafter, referred to as 
LEVs) showed less cytotoxicity than whole cell lysates of 
L. plantarum when used at high protein concentrations 
of 10 μg/mL (Supplementary Figure S2), at which LEVs 
were used in subsequent in vitro assays.
LEV treatment enhances the secretion of 
anti-inflammatory cytokine IL-10 in human skin 
organ cultures
Given that probiotic bacteria, including Lactobacillus, 
modulate host immune responses, we investigated whether 
LEVs could influence immune reactions in a human skin 
organ culture system. LEVs or SEVs, which are strongly 
pathogenic EVs associated with atopic dermatitis 
[11,33,34], were applied twice to human skin specimens 
during a 6-day culture period, and the tissues and culture 
supernatants were harvested for immunohistological and 
cytokine array analyses, respectively (Figure 2(a); 
Supplementary Figure S3). Skin samples in the SEV- 
treated group showed an aberrant epidermal structure, 
with multiple vacuoles, which was quantified by measuring 
the ratio of the number of vacuoles (empty space due to 
cytoplasmic loss) to the total number of cells in the epider-
mis, whereas those in the LEV-treated group did not show 
any damage when compared to vehicle-treated control skin 
samples (Figure 2(a,b); Supplementary Figure S3a). These 
findings suggest that the cultured skin tissues properly and 
differentially respond to external cues. Moreover, SEV 
treatment caused a relatively high increase in the secretion 
of multiple cytokines, including GM-CSF, IL-13, IL-1β, IL- 
10, CXCL9, chemokine C-C motif ligand (CCL)8, IL-2 and 
IL-1α (in descending order), by more than 2-fold differ-
ences when compared to vehicle treatment (Figure 2(c)). In 
contrast, LEV treatment did not increase, but rather sup-
pressed the secretion of most inflammatory cytokines when 
compared to vehicle or SEV treatment, however, it did 
significantly increase the secretion of anti-inflammatory 
IL-10 or that of IL-1β and granulocyte-macrophage col-
ony-stimulating factor (GM-CSF) (Figure 2(c); 
Supplementary Figure S3b). Taken together, these results 
suggest that without causing tissue damage, LEV treatment 
suppresses the secretion of major inflammatory cytokines 
and increases at least the secretion of anti-inflammatory 
cytokine IL-10 in cultured human skin tissues.
LEV treatment induces the differentiation of 
human monocytic THP1 cells towards the 
macrophage lineage
Considering that LEVs induced cytokines including IL-1β, 
GM-CSF and IL-10, which are primarily secreted by 
macrophages [35,36], in cultured human skin tissues 
(Figure 2(c); Supplementary Figure S3b), we postulated 
that they may influence monocyte differentiation and 
Figure 1. Purification of EVs from L. plantarum APsulloc. (a) 
TRPS analysis of ultracentrifugation (UC)- or OptiPrep density 
UC (Density)-purified LEVs. The purification of LEVs using two 
UC methods was performed a minimum of three times and 
representative TRPS results are shown for each method. (b) 
Protein concentration and particle numbers of purified LEVs. 
Conc., concentration; No., number. (c) Bio-TEM and cryo-EM 
image analyses of density-purified LEVs. The outlined LEV 
images are enlarged and the lipid bilayer indicated by black 
and white arrows. Black and white arrowheads indicate the 
potential double membrane of the vesicles. Scale bars, 200 nm.
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macrophage activation. The mature yet inactive state of 
macrophages (naïve M0) are differentiated from mono-
cytes that have migrated into tissues and are subsequently 
polarized into pro-inflammatory M1, or anti- 
inflammatory and tissue-repairing M2 macrophages, all 
of which secrete IL-10 [21,35,37]. Once monocytes become 
differentiated into the macrophage lineage, they reportedly 
express several markers including cluster of differentiation 
14 (CD14), intercellular adhesion molecule 1 (ICAM-1) 
and C-C chemokine receptor type 2 (CCR2) in different 
patterns. CD14, as a co-receptor of TLR4, detects bacterial 
LPS and is highly expressed in monocytes and most tissue 
macrophages [38]. ICAM1, one of the specific markers of 
activated macrophages, participates in the binding of 
immune cells to endothelial cells for extravasation 
[39,40]. Meanwhile, CCR2, a receptor for CCL2 (monocyte 
chemoattractant protein-1), has a unique role in monocyte 
chemotaxis and is lost upon monocyte differentiation [41]. 
Thus, as a first step, we investigated whether LEV treat-
ment can induce the differentiation of human THP1 
monocytic cells towards the macrophage lineage by exam-
ining the expression patterns of these genes.
In general, monocytes differentiate into the macro-
phage lineage upon exposure to PMA [42,43]. When 
THP1 cells in suspension culture were treated with 
PMA for 48 h, they significantly adhered to the surface 
(Figure 3(a)), indicating that they had transitioned to 
activated macrophages [42,43]. Moreover, in PMA- 
treated cells, gene expression of CD14 and ICAM-1 was 
significantly increased, whereas that of CCR2 was 
decreased (Figure 3(b)). Thus, THP1 cells properly 
responded to PMA by differentiating into macrophages. 
In the same way, LEV treatment induced the adherence 
of THP1 cells to the surface (Figure 3(a)), and signifi-
cantly upregulated the expression of CD14 and ICAM-1 
and downregulated that of CCR2 compared to treat-
ments with the vehicle or medium concentrates, to 
a greater extent than that observed upon PMA treatment 
(Figure 3(b)). Furthermore, density-purified LEVs 
showed much stronger activity in regulating the expres-
sion of these genes (Figure 3(b)), confirming the biolo-
gical effects driven by UC-purified LEVs. The expression 
patterns of CD14 in different treatments, which were 
normalized by G6PD, were further verified using two 
other reference genes, ACTB and RPL32 
(Supplementary Figure S4). These results suggest that 
LEV treatment induces the differentiation of monocytic 
cells into the macrophage lineage even in the absence of 
PMA, possibly controlling the fate of monocytes.
Figure 2. LEV treatment enhances the secretion of anti- 
inflammatory cytokine IL-10 in human skin organ cultures. 
Human cultured skin tissues were treated twice with vehicle 
(HBS), LEVs (50 μg/mL), or SEV (50 μg/mL) during a 6-day culture 
period. Tissues and supernatants were harvested on day six for H&E 
staining and cytokine array analysis (n = 2; two independent tissue 
samples). (a) Scheme of bacterial EV treatment of human skin 
cultures and H&E staining. The outlined area is enlarged. Scale 
bars, 100 μm. (b) Abnormality of the epidermis was quantified by 
measuring the ratio of the number of vacuoles (empty space due to 
cytoplasmic loss) to the total number of cells in the epidermis. Data 
are expressed as the mean ratio ± SEM of three different images 
and statistical significance was analysed by one-way ANOVA. 
****p < 0.0001; ns, non-significant. (c) Representative immunoblot 
images of cytokine array analysis. Markedly increased cytokines by 
LEV and SEV treatments are indicated by red-coloured boxes and 
arrows. Inflammatory cytokines that are preferentially, and signifi-
cantly, increased by SEV treatment are indicated by blue-coloured 
boxes and arrows. Cytokines that are more than 2-fold increased or 
decreased in LEV- or SEV-treated compared to vehicle-treated 
groups are shown left or right, respectively, on the basis of NC/PC 
in the graph (red line for 2-fold increase; green line for 2-fold 
decrease). The average fold change in LEV- or SEV- treated groups 
relative to vehicle control was determined by densitometry using 
ImageJ (https://imagej.nih.gov/ij/). NC/PC, negative control/positive 
control of the spots in cytokine array.
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LEV treatment enhances the expression of 
M2-polarized cell markers
Based on the fact that LEVs can induce monocyte differ-
entiation to the macrophage lineage, which are subse-
quently polarized to M1 or M2 macrophage states, as 
a next step, we extensively analysed the mRNA expres-
sion of a series of cell markers related to either M1 or M2 
macrophages, which have been described elsewhere [18– 
22,35], using RT-qPCR in response to LEV treatment. 
The M1 or M2-polarized genes showing significantly 
increased mRNA levels in LEV-treated compared to vehi-
cle-treated cells were highlighted (Figure 4(a)). Among 
M1-polarized cell markers, LEV treatment upregulated 
the expression of IL-15, suppressor of cytokine signalling 
3 (SOCS3), and CD80 [21,44,45]. However, it had no 
significant effect on the expression of other M1 macro-
phage markers, such as CD68 [21], TLR2/TLR4 [46], 
which are highly expressed in THP1 cells 
(Supplementary Figure S5), and human leukocyte anti-
gen-DR alpha (HLA-DRα) [18,21] (Figure 4(a,b)). In 
contrast, the majority of M2-related genes, including 
CD209 [47], C-type lectin domain family 5-member 
A (CLEC5A) [48], CD200 R [49], sphingosine kinase 1 
(SPHK1), class A scavenger receptor 1 (SRA1) [50], IL1 
receptor, type II (IL1R2) [49], and CD163 [51], were 
significantly increased in LEV-treated, compared to vehi-
cle-treated, cells (Figure 4(a,c)). The functional activity of 
LEVs in regulating the expression of macrophage- 
polarized genes was further verified using density- 
purified LEVs, which did not significantly increase the 
expression of M1-related genes (CD68, TLR2, HLA-DRα) 
, however did increase M2-related genes (CLEC5A, SRA, 
CD163), and was specific when considering the effects 
driven by medium concentrates (Supplementary Figure 
S6). Moreover, among M2-related cell markers, not all of 
which were increased by M2-polarizing factors (IL-4/IL- 
13), the gene expression patterns of SPHK1 and CD163 
after LEV treatment were similar to those induced by IL- 
4/IL-13 treatment (Supplementary Figure S7a,c). Taken 
together, although LEV treatment elicited pleiotropic 
responses in THP1 cells, the overall mRNA expression 
pattern of macrophage markers in LEV-treated THP1 
cells showed a significant bias towards M2 polarization.
Gene expression profiling of secretory proteins 
after LEV treatment reveals a preferential 
differentiation of THP1 cells to M2b macrophages
We further examined the mRNA expression profile of 
chemokines after LEV treatment in the presence of PMA 
to activate THP1 cells. Chemokines associated with differ-
ent subtypes of macrophages have been described else-
where [21,35,52]. The mRNA expression of chemokine 
genes that are supposedly stimulated by M1 macrophages 
was not significantly different between LEV-treated and 
vehicle-treated groups, although some chemokines were 
slightly upregulated by LEV treatment (Figure 5(a,b)). 
Among the chemokines related to three subtypes of M2 
macrophages, only M2b macrophage-related chemokines 
were significantly increased by LEV treatment (Figure 5(a, 
c)), meanwhile, CCL23 and CCL24, which are characteristic 
of M2a macrophages, were significantly downregulated 
(Figure 5(a)). The expression of CXCL13 and CCL18, 
which are specific for M2c macrophages [52], was hardly 
affected (Figure 5(a)). Of M2b-related chemokines 
Figure 3. LEV treatment induces the differentiation of human 
monocytic THP1 cells towards the macrophage lineage. (a) Bright- 
field microscopic images of THP1 cells in culture. THP1 cells in 
suspension were treated with vehicle (HBS), PMA (10 nM), medium 
conc. (medium concentrates, 10 μg/mL), or LEVs (10 μg/mL) for 48 h. 
Magnification, 100 ×. (b) THP1 cells were treated with medium conc. 
(10 μg/mL), LEVs (10 μg/mL), PMA (10 nM), or density-purified LEVs 
(density-LEVs, 10 μg/mL) for 48 h. The mRNA expression of activated 
macrophage-specific genes was analysed by RT-qPCR. Glucose- 
6-phosphate dehydrogenase (G6PD) was used for normalization. 
Data are expressed as the mean fold change ± SEM of triplicate 
measurements and statistical significance was analysed by one-way 
ANOVA.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns, non-significant. 
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Figure 4. LEV treatment enhances the expression of M2-polarized cell markers. THP1 cells were treated with LEVs (10 μg/mL) for 
48 h. (a) mRNA expression of markers specific for M1 or M2 macrophages was analysed by RT-qPCR. G6PD was used for 
normalization. Statistically significant fold changes (FC) are indicated in different colours according to the increased degree (light 
grey, 1.5 < FC < 5; medium grey, 5 < FC < 10; dark grey, 10 < FC). -, non-significant. (b) mRNA expression of representative M1 
macrophage-specific surface markers. ns, non-significant. (c) mRNA expression of M2 macrophage-specific markers. Data in (a-c) are 
expressed as the mean fold change ± SEM of triplicate treatments and statistical significance was analysed by Student’s t-tests.
*p < 0.05, **p < 0.01, ***p < 0.001. 
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Figure 5. Gene expression profiling of secretory proteins after LEV treatment reveals a preferential differentiation of THP1 cells to 
M2b macrophages. THP1 cells were pre-incubated with PMA (10 nM) for 48 h and treated with vehicle (HBS) or LEVs (10 μg/mL) for 
an additional 48 h. (a) mRNA expression of M1- and M2-specific chemokines was analysed by RT-qPCR. G6PD was used for 
normalization. Statistically significant fold changes (FC) are indicated in different colours according to the increased degree (light 
grey, 1.5 < FC < 5; medium grey, 5 < FC < 10). -, non-significant. (b, c) mRNA expression of representative M1 (b) and M2b (c) 
macrophage-specific chemokines. ns, non-significant. (d) mRNA expression of M2 macrophage-specific cytokines as determined by 
RT-qPCR. Data in (a-d) are expressed as the mean fold change ± SEM of triplicate treatments and statistical significance was 
analysed by Student’s t-tests.
*p < 0.05, **p < 0.01, ***p < 0.001. 
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increased by LEV treatment, the expression of CXCL1 and 
CCL20, and not CCL1, CXCL2 or CXCL3, were increased 
in M2-inducing conditions by IL-4/IL-13 treatment 
(Supplementary Figure S7b,c), suggesting that chemokine 
expression after LEV treatment is at least in part similar to 
that in M2-inducing conditions although different stimu-
lating factors are required to induce specific subtypes of M2 
macrophage. Among various cytokines, IL-10, IL-1β, and 
IL-6, which are M2 macrophage-characteristic cytokines 
[24,53–55], were barely expressed in PMA-treated THP1 
cells; however, their expression was significantly upregu-
lated upon LEV treatment (Figure 5(d)). This result was in 
line with the fact that in human skin organ cultures, the 
protein levels of IL-1β and IL-10 were increased by more 
than 2-fold upon LEV treatment (Figure 2(b)). Taken 
together, these findings indicate that LEV treatment upre-
gulates the expression of secretory proteins specific for M2 
macrophages, especially, M2b macrophages, implying that 
LEVs can regulate macrophage polarization during mono-
cyte/macrophage transition towards the anti-inflammatory 
or tissue-repairing alternative M2 state in the skin.
LEV treatment downregulates inflammation-induced 
expression of M1 macrophage cell-surface markers
Next, we investigated whether LEVs could alleviate inflam-
mation-related phenomena. IFN-γ and LPS are used to 
evoke inflammatory responses and to drive monocytes 
into M1 macrophages [43]. Thus, THP1 cells were treated 
with LEVs and/or IFN-γ and LPS in the presence or 
absence of PMA to examine whether LEVs interfere with 
M1 induction. The expression of HLA-DRA, which is 
upregulated in M1 macrophages upon exposure to pro- 
inflammatory stimuli [21,56], was not significantly chan-
ged by LEVs per se (Figure 4(a,b)), but was markedly 
upregulated under M1-inducing conditions (Figure 6(a)). 
However, this upregulation was significantly inhibited by 
LEV treatment before or after M1 induction by IFN-γ and 
LPS. The inhibitory effect of LEVs under M1-inducing 
conditions was also observed in PMA-free conditions 
(Figure 6(b)). These results suggest that LEVs could reduce 
the inflammation-related phenomena associated with M1 
macrophages, possibly by promoting the differentiation of 
naïve macrophages towards the M2 state or by increasing 
the transition of M1 to M2 macrophages.
Bacterial fractions prepared under high pressure 
contain LEV-like nanovesicles and show similar 
effects as LEVs in human skin organ cultures
When EVs are considered as powerful bioactive mate-
rials to promote changes in their targets, one signifi-
cant limitation is the low yield and complicated 
purification procedure of EVs. To overcome this in 
mammalian cells, EV-mimetic nanovesicles have been 
produced from stem cells or immune cells via multiple 
serial extrusions [57,58]. Based on a similar concept, 
we manufactured LEV-like vesicles using high pressure 
and successive filtration and ultrafiltration procedures 
to efficiently collect the nanosized materials. According 
to bio-TEM and TRPS analyses, bacterial fractions after 
this process (termed Lactobacillus ferment lysates, 
LFLs) included nanosized vesicles with an average dia-
meter of 173 ± 59.6 nm, yielding approximately 
1.97 × 108 particles per mg proteins (Figure 7(a)). In 
human skin organ cultures, LFL-treated tissues showed 
no damage to the epidermis at the same protein con-
centration as LEVs and had increased expression of IL- 
1β, GM-CSF, and IL-10, similar to LEV-treated tissues 
(Figure 7(b–e)). Although LFLs were less effective than 
LEVs in down-regulating inflammatory cytokines, save 
for PDGF-BB, TPO and leptin, which were all shown 
to be decreased by 0.5-fold or less in LEV-treated 
tissues (Figure 2(c)), their increase in LFL-treated tis-
sues was less than 2-fold compared to vehicle-treated 
tissues, and thus, appeared to be of no significance 
(Figure 7(d,e)). These results suggest that bacteria can 
be processed using high pressure and successive filtra-
tion and ultrafiltration procedures to produce bioactive 
materials comprising EV-like, small-sized vesicles that 
can be used as an alternative for the treatment of 
human skin, without inducing damage.
Figure 6. LEV treatment downregulates inflammation-induced 
expression of the M1 macrophage cell-surface marker, HLA- 
DRα. Human THP1 monocytes at day 1 post plating were pre- 
incubated with 10 nM PMA. PMA was maintained during the 
treatment period (A) or washed out after 48 h (b). On days 3 
and 5, the cells were treated with LEVs (10 μg/ml) or 20 ng/ml 
of IFN-γ and 10 pg/ml of LPS for 48 h. On day 7, the cells were 
harvested and HLA-DRα mRNA expression was analysed by RT- 
qPCR. G6PD was used for normalization. Data are expressed as 
the mean fold change ± SEM of triplicate measurements and 
statistical significance was analysed by one-way ANOVA.
*p < 0.05, ***p < 0.001; ns, non-significant. 
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Discussion
Probiotics are administered for their health benefits, 
primarily for immune modulation. As a representative 
probiotic species, L. plantarum acts not only on the 
mucosal immune system, but also on the human skin 
[59,60]. However, the detailed mechanism underlying 
its beneficial effects on the skin has not been eluci-
dated. Here, we report for the first time that EVs 
derived from L. plantarum preferentially induce mono-
cyte differentiation into M2 macrophages in human 
THP1 cells.
Macrophages play a key role in innate immune surveil-
lance, and proper activation of these cells upon exposure to 
microenvironmental cues is vital for tissue homoeostasis. 
In particular, macrophages are pleiotropic and functionally 
diverse, and are capable of changing their activation state 
(M1 or M2) in response to growth factors and external 
cues, such as cytokines, chemokines, microbes and micro-
bial products. In case of failure to switch from the initial 
inflammatory M1 to the anti-inflammatory and tissue- 
repairing M2 state, the increased M1 macrophages rein-
force a pro-inflammatory environment and generate 
chronic inflammation associated with the phenotypes of 
various inflammatory skin disorders such, as atopic der-
matitis and psoriasis [26,61–63]. Based on extensive ana-
lyses of macrophage-associated cellular marker, 
chemokine and cytokine gene expression, LEV-treated 
THP1 cells were found to be primarily differentiated into 
M2 macrophages, especially, the M2b subtype, which is 
known to release pro-inflammatory cytokines (e.g., IL-1β, 
IL-6 and TNF-α) as well as the anti-inflammatory cytokine 
IL-10 and low levels of IL-12 [24]. Most of these cytokines 
were observed in LEV-treated human skin organ cultures 
and in LEV-treated THP1 cells (Figures 2(c) and 5(d); 
Supplementary Figure S3b). Given that M2b macrophages 
exert strong immune-regulatory and anti-inflammatory 
effects, thereby regulating the breadth and depth of the 
immune response [24], LEVs may relieve hyperinflamma-
tory conditions by regulating macrophage polarization. 
Or, LEVs may reduce inflammatory conditions by stimu-
lating M2-associated signalling in M1 macrophages. 
Considering these capabilities, LEVs could be used to 
improve hyperinflammatory skin conditions and disor-
ders. Furthermore, LEVs were less cytotoxic than bacterial 
cell lysates at the same protein concentrations 
(Supplementary Figure S2), which supports the utilization 
of LEVs as efficient anti-inflammatory materials across 
various protein concentrations. However, taking into 
account the differential cytotoxic effect between LEVs 
Figure 7. Bacterial fractions prepared under high pressure 
contain LEV-like nanovesicles and show similar effects as 
LEVs in human skin organ cultures. (a) Bio-TEM image of 
LFLs (left) and TRPS analysis for mean diameter and particle 
number of LFLs (right). The outlined LFL images (1–4) are 
enlarged and additional large vesicles (5, 6) are shown. 
Scale bars, 200 nm. (b) Images of H&E staining of human 
skin cultures after LFL treatment. The cultured tissues were 
treated with vehicle, LEVs, or LFLs (each 50 μg/ml) twice 
over a 6-day culture period as indicated in Figure 2a. (c) 
Abnormality of the epidermis was quantified by measuring 
the ratio of the number of vacuoles (empty space due to 
cytoplasmic loss) to the total number of cells in the epi-
dermis. Data are expressed as the mean ratio ± SEM of 
three different images and statistical significance was ana-
lysed by one-way ANOVA. Ns, non-significant. (d, e) 
Cytokine array analysis of culture supernatants and repre-
sentative blot image. Markedly increased cytokines by LFL 
treatment are indicated by red-coloured arrows and boxes. 
Cytokines that were increased by more than 2-fold in LFL- 
treated compared to vehicle-treated groups or decreased 
by 0.5-fold or less in LEV-treated but increased in LFL- 
treated compared to vehicle-treated groups were shown 
left or right, respectively, on the basis of NC/PC in the 
graph (red line for 2-fold increase; green line for 2-fold 
decrease). The average fold change in LFL-treated groups 
relative to vehicle control was determined by densitometry 
using ImageJ. NC/PC, negative control/positive control of 
the spots in cytokine array.
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and bacterial cell lysates as well as the limited supply of 
tissue samples available for the current study, which 
resulted in the use of only one high dose of LEVs for 
in vitro (10 μg/mL) and ex vivo (50 μg/mL) treatments, 
there may be more efficient doses or concentrations of 
LEVs to sufficiently induce or verify their biological effects. 
Therefore, it is recommended to test LEV-driven effects at 
various protein concentrations to validate the effects and to 
establish the potential for industrial applications. In addi-
tion, LFLs prepared by repetitive bacterial cell rupture 
under high pressure followed by ultrafiltration may be 
used as LEV-like vesicles that can be produced at a low 
cost, although these may be less effective at down- 
regulating inflammatory cytokines compared to LEVs, 
perhaps due to their larger size, or their potential of con-
taining partially ruptured bacterial cell lysates.
Which bacterial EV factors regulate monocyte dif-
ferentiation and M2 macrophage polarization remains 
to be investigated. It has been reported that lipoteichoic 
acid (LTA) can regulate macrophages via TLRs, among 
which TLR2 is responsible for immune responses, fol-
lowed by NF-κB signalling-mediated cytokine produc-
tion [64,65]. Unlike S. aureus LTA, LTA from 
L. plantarum has various beneficial effects in humans 
[66]. Given that EVs, which include LTA or LPS for 
gram-positive or gram-negative bacteria, respectively, 
are more effective in evoking cellular responses than 
bacterial cell extracts and purified toxins [1,4,5], we 
speculated that LEVs could elicit multifaceted and 
strong immunomodulatory activities through signalling 
between vesicular LTA and TLRs, especially TLRs 2 
and 4, on THP1 cells (Supplementary Figure S5). 
However, we do not exclude the possibility that other 
bioactive molecules, including proteins, lipids, nucleic 
acids and toxins trapped in LEVs, may also be involved 
in this regulation. Indeed, the genetic loci in 
L. plantarum involved in the modulation of the secre-
tion of anti-inflammatory IL-10 and pro-inflammatory 
IL-12 in human mononuclear cells were identified 
through an analysis of 42 strains: these loci included 
genes encoding the phosphotransferase system, 
quorum-sensing system and bacteriocin biosynthesis 
and transport [67], implying the involvement of 
a complex of bacterial factors in the cytokine response 
in innate immune cells. In this regard, it will be inter-
esting to investigate the protein or lipid components 
specifically, or preferentially, enriched in L. plantarum 
APsulloc-derived LEVs and LEV-like vesicles through 
proteomic or lipidomic analyses and to compare their 
profiles to those of the parent cells, or EVs derived 
from other L. plantarum strains or gram-positive bac-
teria. Moreover, EVs are transported into recipient cells 
via several mechanisms, including receptor-mediated 
endocytosis, direct fusion, phagocytosis and caveolae- 
or clathrin-mediated endocytosis [68]. Hence, to deter-
mine which uptake pathways and signalling molecules 
are involved in LEV-evoked cellular responses would 
be helpful to interpret bacterial EV-mediated phenom-
ena in human cells and to develop alternative methods 
using bacterial EVs as immunomodulatory materials.
In human skin organ cultures, pathogenic SEVs 
increased the levels of multiple inflammatory cytokines, 
including IL-13, CXCL9, CCL8, IL-2 and IL-1α, as well as 
the anti-inflammatory cytokine IL-10. Given that IL-13, 
which is dominant in atopic dermatitis pathological con-
ditions [69], CXCL9, which predominantly mediates 
lymphocytic infiltration to the inflammatory sites [70], 
CCL8, which is a chemotactic factor for attracting mono-
cytes and lymphocytes [71], and IL-2, which is primarily 
secreted by T cells in response to microbial infection [72], 
are highly associated with inflammatory responses, SEVs 
are indeed representative pathogenic materials that have 
a strong impact on skin pathophysiology, as indicated in 
previous studies where SEVs induced and exacerbated 
atopic dermatitis-like skin inflammation in part by 
recruiting immune cells to activated microvascular 
endothelial cells [11,33,34]. Nonetheless, the increased 
IL-10 in SEV-treated skin tissues might be a natural 
response driven by M2 macrophages or regulatory 
T (Treg and Tr1) cells to induce immune tolerance 
under prolonged inflammatory conditions [73], as the 
culture was maintained for six days (Figure 2(a)). In 
contrast to SEVs, LEVs did not induce these inflamma-
tory cytokines, but rather increased the expression of 
certain cytokines, including IL-10, IL-1β and GM-CSF. 
Although IL-1β and GM-CSF have been defined as pro- 
inflammatory cytokines, they can polarize macrophages 
into M2-like functional phenotypes or act as an anti- 
inflammatory/regulatory cytokine, respectively, in the 
presence of relevant factors [20,36], suggesting the pre-
sence of pleiotropic dual activities for these cytokines in 
dose- and context-dependent manners. Therefore, LEVs 
can serve as anti-inflammatory and immunomodulatory 
substances by inducing secretion of these cytokines with-
out inducing inflammatory cytokines.
In summary, our results suggest that without causing 
tissue damage, LEVs induce secretion of the anti- 
inflammatory cytokine IL-10, along with immunomodu-
latory cytokines IL-1β and GM-CSF in human skin organ 
cultures, and induce monocyte-to-macrophage transition, 
and macrophage polarization towards the M2b state 
in vitro. Therefore, LEVs could be used as anti- 
inflammatory and immunomodulatory substances for cor-
recting the imbalance between M1 and M2 macrophages, 
thereby improving hyperinflammatory skin conditions 
and the phenotypes of inflammatory skin disorders.
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